BIOLASE, INC.
Schedule II — Consolidated Valuation and Qualifying Accounts and Reserves
For the Years Ended December 31, 2020, 2019, and 2018
(in thousands)
|
|
Balance at
|
|
|
Charges
|
|
|
|
|
|
|
|
|
|
|
|
Beginning
|
|
|
(Reversals) to Cost
|
|
|
|
|
|
|
Balance at
|
|
|
|
of Year
|
|
|
or Expenses
|
|
|
Deductions
|
|
|
End of Year
|
|
Year Ended December 31, 2020:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Allowance for doubtful accounts
|
|
$
|
2,531
|
|
|
$
|
1,488
|
|
|
$
|
(2
|
)
|
|
$
|
4,017
|
|
Allowance for sales returns
|
|
|
210
|
|
|
|
87
|
|
|
|
(35
|
)
|
|
$
|
262
|
|
Allowance for tax valuation
|
|
|
53,222
|
|
|
|
2,813
|
|
|
|
—
|
|
|
$
|
56,035
|
|
Year Ended December 31, 2019:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Allowance for doubtful accounts
|
|
$
|
850
|
|
|
$
|
1,827
|
|
|
$
|
(146
|
)
|
|
$
|
2,531
|
|
Allowance for sales returns
|
|
|
210
|
|
|
|
—
|
|
|
|
—
|
|
|
|
210
|
|
Allowance for tax valuation
|
|
|
46,967
|
|
|
|
6,366
|
|
|
|
(111
|
)
|
|
|
53,222
|
|
Year Ended December 31, 2018:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Allowance for doubtful accounts
|
|
$
|
802
|
|
|
$
|
469
|
|
|
$
|
(421
|
)
|
|
$
|
850
|
|
Allowance for sales returns
|
|
|
210
|
|
|
|
—
|
|
|
|
—
|
|
|
|
210
|
|
Allowance for tax valuation
|
|
|
40,866
|
|
|
|
6,101
|
|
|
|
—
|
|
|
|
46,967
|
|
|